ACTRIMS 2021 | COVID-19 severity in patients with MS

Carlos Pérez, MD, The University of Texas Health Science Center at Houston, Houston, TX, discusses a large cohort study of COVID-19 infection outcomes in 800 patients with multiple sclerosis (MS) and 1600 healthy controls. The analysis found that infection severity did not differ in the MS cohort in comparison to control participants. The impact of specific disease modifying therapies in the MS cohort was also investigated and found that no treatment caused a more severe infection compared to patients receiving no therapy. This interview took place during the ACTRIMS Forum 2021.